June 18th, 2018

A full text version of this article is available.
To access article obtain online access here or login
Methotrexate on a 21-Day Cycle for Low-Risk Gestational Trophoblastic Neoplasia
Authors:  J. Diaz, M.D., M. B. Thomas, M.B.B.S., C. Paz-Pabon, M.D., and E. Hernandez, M.D.
  OBJECTIVE: To perform an outcome analysis of patients with low-risk gestational trophoblastic neoplasia (GTN) treated with a 5-day intramuscular methotrexate (MTX) regimen on a 21-day cycle.

STUDY DESIGN: A retrospective review of 31 patients with low-risk GTN treated with a 5-day MTX regimen.

RESULTS: A total of 31 patients with low-risk GTN (WHO score <7) received single-agent MTX at a dose of 0.4 mg/kg daily for 5 days every 21 days (mean number of cycles, 3; 83% remission). The only significant toxicity encountered was grade 2 stomatitis in 8 (26%) patients.

CONCLUSION: A 5-day MTX regimen given every 21 days is convenient, well-tolerated and effective for patients with low-risk GTN.
Keywords:  chemotherapy, gestational trophoblastic neoplasia, methotrexate
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from